Rani Therapeutics Holdings (RANI) 주식 개요
라니 테라퓨틱스 홀딩스는 미국에서 고통스러운 주사를 대체하여 환자, 의사 및 의료 시스템을 위해 생물학적 제제 및 약물을 경구 투여할 수 있는 기술에 중점을 둔 임상 단계의 바이오 치료제 회사로 운영되고 있으며, 미국 내 환자, 의사 및 의료 시스템을 위해 생물학적 제제 및 약물을 경구 투여할 수 있는 기술에 중점을 두고 있습니다. 자세히 보기
RANI Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rani Therapeutics Holdings, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$0.74 |
| 52주 최고가 | US$3.87 |
| 52주 최저가 | US$0.39 |
| 베타 | 0.76 |
| 1개월 변동 | -22.54% |
| 3개월 변동 | -9.22% |
| 1년 변동 | 33.32% |
| 3년 변동 | -82.14% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -93.31% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.내러티브 업데이트 • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.Recent updates
내러티브 업데이트 • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.내러티브 업데이트 • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.내러티브 업데이트 • Apr 27
RANI: Obesity Capsule Trial Progress Will Support Strong Future Upside Potential
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing a balance between slightly adjusted revenue growth, profit margin expectations, and a modestly lower future P/E assumption. Valuation Changes Fair Value: $11.00 remains unchanged, indicating no adjustment to the core valuation estimate.내러티브 업데이트 • Apr 12
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts maintained their $11.00 price target for Rani Therapeutics Holdings, citing only marginal tweaks in their long term growth and P/E assumptions rather than a change in their overall view of the company. Valuation Changes Fair Value: $11.00 remains unchanged, with no adjustment to the headline valuation figure.
새로운 내러티브 • Mar 31
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 29
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts have kept their price target for Rani Therapeutics Holdings steady at $11.00, reflecting updated assumptions for revenue growth, profit margin, and future P/E that broadly balance each other out in their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity (Key Developments).분석 기사 • Mar 28
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...내러티브 업데이트 • Mar 10
RANI: Obesity Capsule Trial Progress Will Support A More Optimistic Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing updated assumptions about very large revenue growth expectations, a stronger projected profit margin near 21%, and a higher anticipated future P/E multiple as key drivers within their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).내러티브 업데이트 • Feb 24
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing largely steady assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E as reasons to maintain their existing view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist, for potential obesity treatment (company announcement).내러티브 업데이트 • Feb 09
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts kept their fair value estimate for Rani Therapeutics Holdings steady at US$11.00, citing offsetting tweaks to key assumptions such as a slightly higher discount rate, a modestly different revenue growth outlook, a small adjustment to projected profit margins, and a marginally lower future P/E. What's in the News Rani Therapeutics Holdings started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in single and multiple dosing.내러티브 업데이트 • Jan 25
RANI: Obesity Trial Progress And Index Inclusion Will Support A Stronger Outlook
Analysts have kept their US$11.00 price target for Rani Therapeutics Holdings unchanged, citing only fine tuned inputs in discount rate, revenue growth, profit margin and future P/E assumptions that collectively do not shift their overall valuation view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial of RT-114, an oral RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).내러티브 업데이트 • Jan 11
RANI: Future Obesity Trial Progress Will Support A Stronger Bullish Outlook
Analysts have raised their fair value estimate for Rani Therapeutics Holdings from US$9.00 to US$11.00. They cite updated assumptions on revenue growth, profit margin and a higher future P/E multiple as the main factors behind the new price target.
내러티브 업데이트 • Dec 26
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Analysts have nudged their price target for Rani Therapeutics Holdings slightly higher to 9.25 dollars, reflecting modestly improved long term growth and profitability assumptions despite largely unchanged valuation inputs. What's in the News Rani Therapeutics was added to the NASDAQ Biotechnology Index, increasing its visibility among biotech investors (Index Constituent Adds).내러티브 업데이트 • Dec 11
RANI: Licensing Deal And Capital Raise Will Support Future Platform Upside
Analysts have modestly reaffirmed their outlook on Rani Therapeutics Holdings, keeping the price target effectively unchanged at approximately 9.25 dollars. They continue to view the company’s long term revenue growth and margin profile as supportive of its elevated future valuation multiple.내러티브 업데이트 • Nov 27
RANI: Recent Licensing Agreement Will Drive Platform Expansion and Revenue Potential
Analysts have lowered their price target for Rani Therapeutics Holdings from $9.50 to $9.25. They cited updated estimates of growth and profit margin impacts on future valuation.Seeking Alpha • Nov 05
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Summary Rani Therapeutics Holdings, Inc. targets a new potential oral delivery of biologic drugs via the RaniPill. This could eventually replace injections and improve patient adherence. Their pipeline has RT-102 (osteoporosis), RT-111 (psoriasis), and RT-114 (obesity with ProGen). Interestingly, RANI anticipates initiating RT-114’s Phase 1 trials during 2H2025. So, their IP remains clearly in the very early stages for now. Still, their partnership with Chugai added much upfront cash payments and up to $175 million milestone payments. Overall, RANI stock still appears somewhat overvalued after the recent equity raises. And their IP is highly speculative. So, I feel a neutral Hold makes sense for now. Read the full article on Seeking Alpha내러티브 업데이트 • Nov 04
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook. What's in the News Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025.내러티브 업데이트 • Oct 21
Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.내러티브 업데이트 • Aug 15
RT-114 And Pill Technology Will Transform Obesity Treatments
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
새로운 내러티브 • Apr 09
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.분석 기사 • Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 08
Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Rani Therapeutics (NASDAQ:RANI) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’s drug pipeline. Under the loan agreement, company will receive $15M of the initial $30M tranche at closing, with the remaining $15M available for draw at the company’s discretion in Q4 2022. Company has the right to request an additional $15M of funds in the future if certain conditions and milestones are met. Interest at a variable rate equal to the greater of (1) prime, plus 5.6% and (2) 10.35%분석 기사 • Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...주주 수익률
| RANI | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | -5.9% | 9.0% | -2.6% |
| 1Y | 33.3% | 48.8% | 20.0% |
수익률 대 산업: RANI은 지난 1년 동안 48.8%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: RANI은 지난 1년 동안 20%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| RANI volatility | |
|---|---|
| RANI Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: RANI의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: RANI의 주간 변동성은 지난 1년간 39%에서 15%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2012 | 70 | Talat Imran | www.ranitherapeutics.com |
는 미국에서 고통스러운 주사를 대체하여 환자, 의사 및 의료 시스템을 위해 생물학적 제제 및 약물을 경구 투여할 수 있는 기술에 중점을 둔 임상 단계 바이오 치료제 회사로 운영되고 있습니다. 올리고뉴클레오타이드, 펩타이드, 단백질, 항체 등 다양한 약물 물질을 전달하기 위한 약물에 구애받지 않는 경구 전달 플랫폼인 라니필 캡슐을 개발하는 회사입니다. 류마티스 관절염 치료를 위해 전임상 단계에 있는 항-TNF-알파 항체 RT-105, 비만 치료를 위해 발견 단계에 있는 RT-116, 희귀질환 치료제 RT-117, 다양한 염증 질환 치료를 위한 우스테키누맙 바이오시밀러 RT-111 등의 제품 파이프라인을 보유하고 있습니다.
Rani Therapeutics Holdings, Inc. 기초 지표 요약
| RANI 기초 통계 | |
|---|---|
| 시가총액 | US$91.96m |
| 순이익 (TTM) | -US$29.44m |
| 매출 (TTM) | US$3.17m |
23.2x
주가매출비율(P/S)-2.5x
주가수익비율(P/E)RANI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| RANI 손익계산서 (TTM) | |
|---|---|
| 매출 | US$3.17m |
| 매출원가 | US$0 |
| 총이익 | US$3.17m |
| 기타 비용 | US$32.61m |
| 순이익 | -US$29.44m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.29 |
| 총이익률 | 100.00% |
| 순이익률 | -929.06% |
| 부채/자본 비율 | 0% |
RANI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/26 17:35 |
| 종가 | 2026/06/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Rani Therapeutics Holdings, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |